ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

计划入组 11 人 · 首次发布于 2022 年 6 月 10 日

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

计划入组 856 人 · 首次发布于 2022 年 4 月 19 日

ECP Combination Study

计划入组 319 人 · 首次发布于 2021 年 9 月 22 日

ECP-104

ECP-103

ECP-105

FUNDACION GECP

Spain

Grupo Unamis Scp

Mexico

ECI Pharmaceuticals LLC

United States

ECP Treatment Shows Promising Results for Steroid-Resistant Chronic GVHD Patients

Impella ECP Heart Pump Demonstrates Safety and Efficacy in High-Risk PCI Patients

J&J's Small-Bore Impella ECP Meets Primary Endpoint in High-Risk PCI Trial